ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1635

Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?

Claudette Farenhorst1, Anniek Van Roon1, Anne van Gessel1, Alja Stel1, Hendrika Bootsma2, Wineke Armbrust1 and Douwe J Mulder1, 1University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

Meeting: ACR Convergence 2021

Keywords: Connective Tissue Disease, Nailfold Capillary Microscopy, Raynaud's phenomenon

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Nailfold capillary microscopy (NCM) is a cornerstone in the diagnosis of Systemic Sclerosis (SSc) in adulthood. Although Raynaud’s phenomenon (RP) is common in childhood, studies on diagnostic methods to differentiate between primary RP (PRP) and secondary RP (SRP) at a young age are scarce. The aim of this study was to determine the value of NCM in differentiating between PRP and SRP in children and adolescents with RP.

Methods: In this nested case-control study, 83 patients diagnosed with RP and having undergone NCM in childhood were retrospectively included. Based on whether they were diagnosed with a connective tissue disease (CTD) during follow-up, patients were classified as PRP or SRP. Patients were considered to have SRP if they had received a CTD diagnosis based on current ACR/ EULAR classification criteria: SSc, Mixed CTD (MCTD) systemic lupus erythematosus (SLE), adult and juvenile idiopathic inflammatory myopathies (IIM), rheumatoid arthritis (RA) primary Sjögren’s syndrome (SS). NCM was judged visually by a vascular technician. PRP and SRP patients were compared on demographics, NCM, and serology. Variables associated with SRP were included in a multivariate logistic regression model. Predictive values were calculated for NCM, ANA positivity, and the combination of NCM and ANA positivity.

Results: At the time of the NCM, the mean age of the RP patients was 15.4±2.3 years (Table 1). Of these patients, 78% were classified as PRP and 22% as SRP at mean follow-up of 6.4±3.20 years. Of the SRP patients, 22% had an undifferentiated CTD, 22% had a MCTD, 17% had SLE, 11% had IIM, 6% had SSc, 6% had SS, 6% had incomplete SLE, 6% had incomplete SSc and 6% had incomplete SS. In total, half of patients had dilated capillaries, 25% had giant capillaries, 22% had capillary los, 17% had hemorrhages. Giant capillaries were confined to patients with SSc (1 out of 1), MCTD (3 out of 4), and IIM (2 out of 2). An SSc-like NCM pattern was observed in only 25%, which did not differentiate between those who developed CTD and those who did not. Of the NCM parameters, only capillary loss was associated with SRP (p=0.01). In a multivariate logistic regression model, capillary loss was an independent predictor (OR=3.98, CI 95% 1.22-12.99) (Table 2). After including ANA in the model, capillary loss was not an independent predictor of SRP. Capillary loss had a sensitivity of 44% and a specificity of 84% for SRP. PRP was correctly predicted in 99%, while SRP was correctly predicted in 27% of the cases by using capillary loss. ANA combined with capillary loss had a sensitivity of 67% and a specificity of 86% (Table 3).

Conclusion: Of all NCM findings, only capillary loss was predictive of SRP in children presenting with RP. Using NCM in childhood should be done with caution since the majority of children developing future CTDs present without specific NCM abnormalities. However, if present, capillary loss on NCM has a high specificity for future CTD. Because of this, we believe NCM could be useful as a screening method to exclude SRP when combined with serology. Our study underlines that future research should determine the predictive value of NCM and its specific abnormalities for individual CTDs in children presenting with RP.

Table 1: Baseline characteristics for the whole study population, and the PRP group and SRP group separately.

Table 2: Multivariate logistic regression model showing predictive value of baseline variables for SRP excluding ANA positivity.

Table 3: Predictive value of logistic regression models comprising different independent variables for prediction of SRP.


Disclosures: C. Farenhorst, None; A. Van Roon, None; A. van Gessel, None; A. Stel, None; H. Bootsma, Bristol Myers Squibb, 2, 5, 6, Roche, 2, 5, Novartis, 2, 6, Medimmune, 2, Union Chimique Belge, 2; W. Armbrust, None; D. Mulder, None.

To cite this abstract in AMA style:

Farenhorst C, Van Roon A, van Gessel A, Stel A, Bootsma H, Armbrust W, Mulder D. Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/nailfold-capillary-microscopy-in-children-with-raynauds-phenomenon-potential-predictive-value-of-capillary-loss-for-future-connective-tissue-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-capillary-microscopy-in-children-with-raynauds-phenomenon-potential-predictive-value-of-capillary-loss-for-future-connective-tissue-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology